Modern medicine’s go-to strategies for cancer treatment are archaic, based on the “cut, poison, burn” model — or surgery, chemotherapy and radiation. The idea of using toxic therapies to destroy tumors should represent a last resort, if used at all, not a first-line treatment. By their very nature, chemotherapy and radiation have devastating effects on… Read More »
Editor’s Note: This article is a reprint. It was originally published June 30, 2019. Cancer kills an estimated 1,600 Americans each day. In China, 8,100 people a day succumb to the disease. It’s so common, it’s a rare individual who does not know someone who has been diagnosed with cancer — which is why the… Read More »
I’ve been a long-term advocate for exercise as a primary treatment option for depression, and now, an overview of systematic reviews1,2,3 shows just how well-reasoned this advice has been. Exercise Is 1.5x More Effective Than Best Antidepressants In all, 97 systematic reviews with meta-analyses of controlled trials assessing the effects of exercise on adult depression,… Read More »
BALTIMORE, July 1, 2021 /PRNewswire/ –Lupin Pharmaceuticals, Inc., the U.S. based wholly-owned subsidiary of global pharma major Lupin Limited (Lupin), announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s supplemental New Drug Application (sNDA) to expand the use of Solosec (secnidazole) to include the treatment of trichomoniasis in adults. Trichomoniasis… Read More »
FDA Grants Accelerated Approval for Aduhelm (aducanumab-avwa) for the Treatment of Alzheimer’s Disease CAMBRIDGE, Mass. and TOKYO, June 07, 2021 (GLOBE NEWSWIRE) — Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Aduhelm™ (aducanumab-avwa) as the first and only Alzheimer’s… Read More »